Literature DB >> 1497800

p53 gene mutations in human endometrial carcinoma.

J I Risinger1, G A Dent, D Ignar-Trowbridge, J A McLachlan, M S Tsao, M Senterman, J Boyd.   

Abstract

Although carcinoma of the uterine endometrium is the most frequently diagnosed malignancy of the female reproductive tract, the molecular genetic features of this tumor have yet to be described in significant detail. Since mutations of the p53 tumor suppressor gene are the single most common genetic alteration found in human malignancies, we examined the hypothesis that p53 mutations occur in human endometrial carcinoma. Sequencing analysis of exons 5-8 revealed point mutations in 3 of 21 (14%) tumors; one mutation was an unusual single-base insertion at codons 176-177, resulting in a premature stop codon, whereas the other two were CGG----TGG transitions at codon 248. Two of these tumors showed reduction to homozygosity at the p53 allele, but one tumor apparently retained heterozygosity. These data indicate that p53 mutations occur in human endometrial carcinoma, although relatively infrequently, and that loss of the normal p53 allele does not necessarily occur with point mutation of the p53 gene in this tumor type.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497800     DOI: 10.1002/mc.2940050403

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.

Authors:  R F Caduff; C M Johnston; S M Svoboda-Newman; E L Poy; S D Merajver; T S Frank
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

2.  Biomarkers in endometrial cancer: Possible clinical applications (Review).

Authors:  Kouji Banno; Iori Kisu; Megumi Yanokura; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Oncol Lett       Date:  2012-03-26       Impact factor: 2.967

3.  Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Authors:  Esra A Akbay; Cristina M Contreras; Samanthi A Perera; James P Sullivan; Russell R Broaddus; John O Schorge; Raheela Ashfaq; Hossein Saboorian; Kwok-Kin Wong; Diego H Castrillon
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

4.  Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target.

Authors:  Ryoichi Asaka; Tsutomu Miyamoto; Yasushi Yamada; Hirofumi Ando; David Hamisi Mvunta; Hisanori Kobara; Tanri Shiozawa
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

Review 5.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

6.  Human endometrial carcinoma cells release factors which inhibit the growth of normal epithelial cells in culture.

Authors:  C D Albright; G J Tsongalis; J H Resau; D G Kaufman
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 7.  Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Authors:  Tanri Shiozawa; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.850

8.  Deletion mapping on chromosome 10q25-q26 in human endometrial cancer.

Authors:  S Nagase; S Sato; F Tezuka; Y Wada; A Yajima; A Horii
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

9.  Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.

Authors:  R Soong; S Knowles; K E Williams; I G Hammond; S J Wysocki; B J Iacopetta
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

10.  p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.

Authors:  Y Soini; T Turpeenniemi-Hujanen; D Kamel; H Autio-Harmainen; J Risteli; L Risteli; K Nuorva; P Pääkkö; K Vähäkangas
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.